The Role of Bacteria in the Pathogenesis of Ulcerative Colitis by Sasaki, Maiko & Klapproth, Jan-Michael A.
Hindawi Publishing Corporation
Journal of Signal Transduction
Volume 2012, Article ID 704953, 6 pages
doi:10.1155/2012/704953
Review Article
The Role of Bacteria in the Pathogenesis of Ulcerative Colitis
MaikoSasakiandJan-MichaelA.Klapproth
Division of Digestive Diseases, Atlanta Veterans Administration Medical Center, Emory University,
Whitehead Biomedical Research Building, Suite 201, 615 Michael Street, Atlanta, GA 30322, USA
Correspondence should be addressed to Jan-Michael A. Klapproth, jklappr@emory.edu
Received 28 July 2011; Accepted 16 January 2012
Academic Editor: Tadashi Matsuda
Copyright © 2012 M. Sasaki and J.-M. A. Klapproth. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Factors implicated in the pathophysiology of ulcerative colitis (UC) are an abnormal immune response, defect in intestinal
epithelial barrier function, and gut microbiota. Currently, it is unclear whether speciﬁc bacterial strains are responsible for
the induction of intestinal inﬂammation, but increased bacterial tissue invasion has been described in aﬀected UC patients.
Further, a quantitative and qualitative microbial imbalance in UC, deﬁned as dysbiosis, has been characterized by an increase
in Rhodococcus spp., Shigella spp.,a n dEscherichia spp., but a decrease in certain Bacteroides spp.. More speciﬁcally, Campylobacter
spp.,Enterobacteriae,andenterohepaticHelicobacter weremoreprevalentintissuesamplefromUCpatientssubjectedtomolecular
detection methods, but not controls. In addition, serologic testing identiﬁed Fusobacterim varium as a potential contributor to the
intestinal inﬂammation in UC. Interestingly, in-situ hybridization studies have shown anti-inﬂammatory Lactobacillus spp. and
Pediococcus spp. were absent in samples from subjects aﬀected by UC. Therefore, dysbiosis is a factor in the pathogenesis of UC.
1.Introduction
The gut microbiota consists predominantly of phyla mem-
bers Bacteroidetes and Firmicutes,a n dt oal e s s e re x t e n to f
Actinobacteria and Proteobacteria [1, 2]. There is an esti-
mated 500 to 1,000 diﬀerent bacterial species represented
throughout the human intestine [3]. The number of colony
forming units has been calculated at a range from 1013 to
1014, exceeding the number of human cells by factor of 10
[4] .T h ee n t e r i cb a c t e r i a lﬂ o r aa saw h o l ei se s s e n t i a lt ot h e
normaldevelopmentandfunctionoftheintestine.Salvageof
unabsorbed carbohydrates, converted into short-chain fatty
acids by bacterial enzymes, is an essential energy source for
intestinal epithelial cell and barrier function. The colonic
microﬂora is also central to the synthesis of vitamins B and
K[ 5], and maintenance of intestinal innate and adaptive
immune response [3]. On the other side, there is mounting
evidence that the intestinal microﬂora can induce, transfer,
and prevent conditions like obesity, type I diabetes, and
inﬂammatory bowel disease (IBD) with a detrimental eﬀect
onhumanhealth[6].Thefocusofthispaperistosummarize
the evidence for a role of enteric bacteria in the pathogenesis
of ulcerative colitis (UC).
Computational data mining by canonical correlation
analysis conﬁrmed the critical and disease-relevant interac-
tion of mucosa-associated bacteria and host in IBD [7].
Bacterial interactions with the host were found to be of cy-
clic nature with an increase in disease inducing bacterial
strains and host immune response during active intestinal
inﬂammation. But dysbiosis, deﬁned as quantitative and
qualitative microbial imbalance in the gut, is only one
factor contributing to intestinal inﬂammation as seen in
UC. Investigating the mucosal immune response, it has been
shown that patients with UC mount an immunoglobulin
response against endogenous bacterial components. In UC,
the DNase-sensitive neutrophil autoantibody with atypical
perinuclear distribution (pANCA) was found to be directed
against two bacterial antigens: an unidentiﬁed 100kDa pro-
tein from Bacteroides caccae and outer membrane porin
C (OmpC) from E. coli strains [8]. Given pANCA’s low
sensitivity, it should not be used as a screening tool for IBD
inthegeneralpopulation,butmightaidindistinguishingUC
from Crohn’s disease (CD) when used in combination with
anti-Saccharomyces cerevisiae antibody (ASCA), in particular
when surgery is entertained. A combination of positive
pANCA and negative ASCA predicted UC correctly in 64%2 Journal of Signal Transduction
of cases [9]. Other more controversial ﬁndings regarding the
role of pANCA in UC include its association with severe,
relapsing and therapy-refractory left-sided disease, early
colectomy for an aggressive course, and higher requirements
for immunomodulatory therapy [9]. Additional immuno-
logical ﬁndings revealed that the intestinal mucosa of pa-
tients suﬀering from UC is inﬁltrated with Th17 cells [10],
stimulated by IL-23, a cytokine released by antigen-pre-
senting cells in response to bacterial stimulation [11]. Also,
genomewide association studies [12] have detected addi-
tional critical factors for the pathogenesis of UC. These
include hepatocyte nuclear factor 4 (HNF4A), a protein reg-
ulating intercellular cell junctions, like desmosomes, tight
and adherence junctions [13], and laminin β1 subunit
(LAMB1), anchoring epithelium to the underlying basement
membrane.Interestingly,lamininhasbeenshownpreviously
to be absent from the surrounding membranes in inﬂamed
tissue section aﬀected by UC [14]. Other genes identiﬁed in
the association studies were E-cadherin (CDH1), a protein
member of adherens junctions and transcription factor
guanine nucleotide binding protein alpha 12 (GNA12).
Common to HNF4A, LAMB1, CDH1, and GNA12 is the
fact that these genes are all involved in the maintenance of
intestinal epithelial cell integrity and barrier function [15].
The ﬁndings outlined above have deﬁned the currently
acceptedhypothesisforthedevelopmentofIBD,“Pathogenic
intestinal bacteria and/or infectious agents initiate and
perpetuate the inﬂammation of the gut through disruption
of tolerance towards the commensal microbiota in an indi-
vidual with genetic vulnerability.” [16].
2.DysbiosisinUlcerative Colitis
Currently, it is not clear which factors initiate or maintain
the inﬂammatory process in UC. There are opposing views
whether an imbalance in gut ﬂora even occurs in UC [17],
but the evidence presented here does suggest that this is
the case. Large epidemiological studies have addressed the
question whether a trigger event lead to dysbiosis in UC. In
a study from Spain with an average follow-up time of 3.5
years, the estimated incidence of developing both CD and
UC was signiﬁcantly elevated in patients with an identiﬁable
episode of acute gastroenteritis [18]. For the control cohort
without an episode of gastroenteritis, the incidence of IBD
was calculated at 29.7/100,000 person years, but it increased
to 68.4/100,000 person years for patients with previously
identiﬁed episode of bacterial intestinal infection. In this
study, the most commonly identiﬁed bacterial pathogen as
a cause of enteric infection was Campylobacter spp., followed
by Salmonella spp. and Shigella spp.. Similarly, a gender and
age-matched study from Denmark identiﬁed an increased
risk for the development of CD and UC after infection with
Campylobacter spp. or Salmonella spp. [19, 20]. The risk
for CD and UC was highest during the ﬁrst year following
infection, in particular for inpatients, and remained elevated
during the ensuing 15 years. These ﬁndings were disputed
in another study from Denmark, which determined the
incidence rate ratio of populations with or without exposure
to Campylobacter spp. or Salmonella spp. [21]. Contrary to
previously published results, the risk of developing CD and
UC wasfound tobe independent of positive or negative stool
studies. The authors concluded that the increased discovery
of previous Campylobacter spp. and Salmonella spp. infection
at the time of diagnosis of CD or UC was due to increased
rates of stool testing, consistent with detection bias.
However, it is still attractive to speculate that an acute
enteric infection leads to possibly chronic changes in intesti-
nal milieu and/or enteric microﬂora, or both. Indeed, there
are a number of excellent studies that have investigated the
quantitative and qualitative changes in the composition of
theentericﬂorainUC.Attemptingtoenumeratethenumber
of bacteria in IBD patients, tissue samples were subjected
to either enumeration by culture or quantitative rRNA
hybridization [22]. Samples from both CD and UC subjects
contained signiﬁcantly more bacteria when compared to
normal control tissue, and a gradual increase was observed
from noninﬂamed to inﬂamed biopsy material [23]. In these
experiments, imaging identiﬁed bacteria localized within the
mucus layer without directly adhering to the underlying
lamina propria. Additional results from another laboratory
also showed increased bacterial adherence and invasion of
epithelial cells and an enhanced inﬂammatory response
[24]. Similarly, when determined by real-time quantitative
PCR, biopsy samples from individuals with newly diagnosed
UC harbored a signiﬁcantly higher number of mucosa-
associated bacteria in comparison to samples obtained from
CD or healthy controls [25]. Similarly, 16S rRNA-based
ampliﬁcation revealed increased total CFU for aerobes,
facultative anaerobes, and Gram negative bacteria in a
pediatric population [26]. At the same time, a decreased
numberofBacteroidesvulgatuswereampliﬁedincomparison
to healthy control subjects. In this study, the only Gram
negative bacterial species identiﬁed in pediatric UC was
Escherichia coli. In an opposing view, qualitative analysis
revealed a similar distribution of unclassiﬁed Bacteroidetes
in UC and healthy control samples [27]. Distinguishing
between the microbiota of inﬂamed and noninﬂamed sam-
ples, it appears that with the onset of inﬂammation, bacterial
diversity declines. These ﬁndings have been supported by
other qualitative studies investigating the enteric ﬂora of
patients with UC. Denaturing gradient gel electrophoresis
with universal and Bacteroidetes-speciﬁc primers and mul-
tivariant analysis revealed reduced diversity of predominant
bacteria commonly found in healthy volunteers [28]. Species
conspicuously absent from the enteric ﬂora in 13 patients
with documented UC included Bacteroides vulgatus, B.
ovatus, B. uniformis,a n dParabacteroides spp.. Similarly, in
a landmark study by Frank et al., abnormal gut ﬂora was
identiﬁed in patients with CD and UC [29]. When subjected
to culture-independent rRNA sequence analysis, common
to both diseases was a reduction of phyla Bacteroidetes
and Firmicutes. Both phyla promote gut health through the
production of short-chain fatty acids, which are the primary
energy source for intestinal epithelial cells, critical for the
maintenance of barrier integrity [30, 31] and suppression of
immune activation [32]. Depletion of short-chain fatty acid-
producing organisms possibly deprives already vulnerableJournal of Signal Transduction 3
intestinal epithelial cells, leading to invasion of commensal
or low-pathogenic bacteria with subsequent activation of
immunocompetent cells.
But dysbiosis, as seen in UC, includes additional patho-
physiological changes relevant to intestinal inﬂammation.
Fluorescence in situ hybridization detected invasive bacteria
in 83% of tissue samples from patients with UC as opposed
to none in negative controls [33]. The organisms invading
terminal ileum and colon of UC aﬀected individuals were
identiﬁed as Proteobacteria, Clostridium, Enterobacteriae,
Bacteroides,a n dPrevotella. These investigations have opened
additional trials attempting to identify a single or multi-
ple disease-speciﬁc bacterial strains. A recently published
study of twins aﬀected and not aﬀected by IBD-identiﬁed
potentially pathogenic bacteria that were more frequently
identiﬁed in patients suﬀering from UC [34]. These strains
included Rhodococcus spp., Shigella spp., Escherichia spp.,a n d
Stenotrophomonas spp.. At the same time, bacteria with anti-
inﬂammatory properties were more frequently identiﬁed
in siblings not aﬀected by UC, including Faecalibacterium
prausnitzii.Ar e d u c t i o ni nF. prausnitzii was recently shown
to be associated with a higher risk of postoperative recur-
rence of CD, as documented by endoscopy at six months
[35]. The proposed anti-inﬂammatory eﬀect of F. prausnitzii
was attributed to the attenuated activation of NF-κBa n d
MAP3K8, with subsequent reduction of IL-8 expression.
3.SpeciﬁcBacteriaIncreasedinUC
Comparing gut tissue samples obtained from patients with
both infectious diarrhea and UC microscopically, both
diseases show a signiﬁcant overlap in pathological ﬁndings
[36]. PCR and sequencing analyses identiﬁed Campylobacter
spp. in 74% of biopsy samples in a cohort of 69 patients
with conﬁrmed UC as opposed to 23% from healthy
controls, even without the history of acute gastroenteritis
[37]. Speciﬁcally, nested PCR for Campylobacter concisus was
positive, and it was more common in UC samples when
compared to healthy controls; 33% versus 11%, respectively.
In addition, Campylobacter ureolyticus was positive in 22%
of UC biopsy material compared to 3% of control samples,
with supporting evidence in a similar study from India
[38]. These ﬁndings led the authors to speculate that a
speciﬁcimmunologicaldefectinUCresultsintheinabilityto
eliminate Campylobacter spp.. Independent of the underlying
host defect, a possible mechanistic explanation for a role of
Campylobacter spp. in the pathogenesis of UC has recently
been provided. Campylobacter jejuni was found to facilitate
internalization and translocation of commensal, noninvasive
E. coli strains via the transcellular and paracellular pathways
in vitro and in vivo [39, 40]. These ﬁndings might indicate
that in UC, Campylobacter spp. induce an inﬂammatory
cascade that starts with an episode of acute gastroenteritis.
Besides Campylobacter spp., ribosomal intergenic spacer
analysis with subsequent sequencing analysis of unique PCR
bands detected 3 to 4 logs higher abundance of Enterobacte-
riae belonging to the B2 and D phylogenetic groups in both
CD and UC [41]. This might be in support of an argument
for the role of speciﬁc bacteria in UC, as pathogenic E. coli
strains belong predominantly to group B2 and to a lesser
degree to group D. In a related study, E. coli isolates from
patients with CD and UC displayed higher-adhesion indices
in comparison to strains from normal controls [42]. E. coli
associated with UC tissue harbor more adhesion/virulence
determinants than strains from CD biopsy samples. More
speciﬁcally, E. coli strains positive for pathogenicity factors
ompA, afae,a n dUSP were more likely to be identiﬁed
in patients suﬀering from UC [43]. As mentioned before,
these E. coli belonged to phylotype B2 and D, and were
associated with active inﬂammation. This particular study
also described an increased intracellular survival of invading
E. coli in macrophage cultures in vitro, consistent with
increased pathogenicity of UC bacterial isolates.
Adding to the list of potentially pathogenic bacteria in
UC, PCR-based methods detected increased enterohepatic
Helicobacter in subjects with CD and UC in comparison to
members of the control population [44, 45]. In contrast to
subjects suﬀering from IBD, the control population had a
higher likelihood of infection with Helicobacter pylori.G i v e n
these results, the authors speculated that cytolethal toxin
from enterohepatic Helicobacter plays a potential role in
the intestinal inﬂammation of IBD. However, the molecular
detection methods identifying Campylobacter spp., E. coli,
and enterohepatic Helicobacter in patients with UC await
conﬁrmation by an alternative method.
Alternatively, serological markers have been used to
implicate speciﬁc bacterial strains in the pathogenesis of UC.
Bacteroides ovatus caused an increased IgG and IgA antibody
response in patients with IBD as opposed to normal controls
[46]. This study identiﬁed and implicated a novel 19.5kDa
prominent antigen in the pathogenesis of both CD and
UC. Similarly, UC patients were more likely to be seropos-
itive for antibodies directed against Fusobacterium varium
antigens (40%) in comparison to normal controls (16%)
[47]. Correlating disease activity with seropositivity, patients
with elevated F. varium immunoglobulins were more likely
to be symptomatic and harbor extensive disease. In vitro
investigations of F. varium by the same group have shown
that this particular commensal strain invades epithelial cell
lines, and induces expression of proinﬂammatory cytokine
mRNAs, including IL-8, TNF-α, MCP-1, and IL-6 [48].
Further, in vivo experiments identiﬁed F. varium to produce
very high concentrations of butyric acid, causing intestinal
lesions in mice, similar to those observed in human UC
[49]. In turn, elevated butyric acid was shown to increase the
activity of proapoptotic pathways with subsequent erosions,
a possible pathophysiological mechanism in UC [50]. These
ﬁndings have led to three clinical trials investigating the
eﬃcacy of antibiotics in UC to speciﬁcally suppress F.
varium [51–53]. Consistently, antimicrobial therapy resulted
in signiﬁcantly decreased CFUs and antibody titers directed
against F. varium, improved endoscopic and histological
scores, and clinical response at 12 months after treatment. In
addition, patients treated with a combination of amoxicillin,
tetracycline, and metronidazole for 14 days were more likely
to discontinue steroid therapy at 3, 6, and 12 months.4 Journal of Signal Transduction
Table 1: Summary of enteric bacteria and their contribution to intestinal inﬂammation in UC.
Role in UC Strain Location Reference
Initiation of inﬂammation
Campylobacter spp. Europe [19, 20]
Salmonella spp. Europe [19, 20]
Shigella spp. Europe [19, 20, 34]
Proinﬂammatory
Campylobacter spp. Europe [37]
Escherichia coli Europe and America [26, 34, 39–43]
Rhodococcus spp. Europe [34]
Stenotrophomonas spp. Europe [34]
Enterohepatic Helicobacter Europe and America [44, 45]
Bacteroides ovatus Asia [46]
Fusobacterium varium Asia [47]
Anti-inﬂammatory
Bacteroides spp. Europe and America [26, 28, 29]
Firmicutes America [29]
Faecalibacterium prausnitzii Europe [34]
Lactobacillus spp. Europe [54]
Pediococcus acidilactici Europe [54]
4.SpeciﬁcBacteriaDecreasedinUC
Itisbecomingincreasinglyclearthatthequalityandquantity
of intestinal microﬂora vary with disease activity, and active
inﬂammation is not solely due to an increase of speciﬁc
bacterial strains. During active UC, anti-inﬂammatory Lac-
tobacillussalivarius,L.manihotivorans,andPediococcusacidi-
lactici were absent in fecal samples analyzed by ﬂuorescence
in situ hybridization [54]. With UC in remission, these
strains reappeared. In a related study, Biﬁdobacterium spp.
were identiﬁed in decreased numbers in both inﬂamed
UC and CD while Lactobacillus spp. was unchanged during
active UC [55]. The same study commented on the reduced
thickness of the mucus layer when compared to controls.
5. Summary and Conclusion
Here we have discussed the roles of enteric bacteria in
UC. The bacterial strains that have been associated with
various roles are summarized in Table 1.I ti sc o n c e i v a b l e
that pathogenic bacteria, including Campylobacter spp.,
Salmonella spp., and other currently unidentiﬁed pathogens,
take the lead in initiating the inﬂammatory process in UC
with an episode of acute gastroenteritis. Pathogenic and
commensal strains and their eﬀector proteins weaken the
intestinal lining through production of high concentrations
of butyric acid and translocation of nonpathogenic bacteria
in genetically susceptible patients with a defect in the in-
testinal epithelial barrier function. Extensive immune acti-
vation due to breakdown of the intestinal barrier provides
bacteria access to the gut mucosal immune system, resulting
in uncontrolled inﬂammation and dysbiosis.
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